Humatrope for short stature
Executive Summary
Lilly's growth hormone Humatrope (somatropin, rDNA origin) approved by FDA for idiopathic short stature July 25. Lilly will not conduct DTC advertising for Humatrope, will market the new indication only to pediatric endocrinologists and will distribute the product through controlled channels, as discussed during FDA's Endocrinologic & Metabolic Drugs Advisory Committee's June 10 review (1"The Pink Sheet" June 16, 2003, p. 28)...
You may also be interested in...
Lilly Humatrope Postmarket Plans: Voluntary Study, No Patient Registry
An assessment of the long-term safety and efficacy of Lilly's Humatrope for idiopathic short stature will rely on a voluntary ongoing postmarket research program
Lilly Humatrope Risk Plan Relies On Limited Promos; Cmte. Wants Registry
Lilly's proposed risk management program for use of Humatrope in non-growth hormone deficient short stature includes an effort to carefully tailor promotions for the pending supplemental indication
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”